Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06104319 · ClinicalTrials.gov registry record · Phase 2
Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT06104319 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 61 participants.
The verdict
NCT06104319, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
The purpose of this study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated. The total study duration for each participant will be approximately 24-36 weeks.
Interventions
- DRUG GSK4532990
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2024-01-22 |
| Est. Completion | 2025-09-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06104319
The ClinicalTrials.gov registry entry for NCT06104319 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK4532990 is the first listed.
NCT06104319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06104319 about?
NCT06104319 is a clinical study titled "Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH". The purpose of this study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated. The total study duration for each participant will be approximately 24-36 weeks.
What is the current status of trial NCT06104319?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2024-01-22. Estimated completion is 2025-09-23.
What interventions are being tested in trial NCT06104319?
The interventions under investigation include: GSK4532990 (DRUG).
Who is sponsoring clinical trial NCT06104319?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.